5,606 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 5,606 shares of the specialty pharmaceutical company’s stock, valued at approximately $625,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Crossmark Global Holdings Inc. lifted its position in shares of Jazz Pharmaceuticals by 23.6% during the third quarter. Crossmark Global Holdings Inc. now owns 5,083 shares of the specialty pharmaceutical company’s stock worth $567,000 after purchasing an additional 970 shares during the last quarter. CWA Asset Management Group LLC bought a new position in Jazz Pharmaceuticals during the 3rd quarter worth approximately $3,197,000. Philip James Wealth Mangement LLC acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $830,000. AlphaCentric Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 40.9% in the 3rd quarter. AlphaCentric Advisors LLC now owns 15,500 shares of the specialty pharmaceutical company’s stock valued at $1,727,000 after acquiring an additional 4,500 shares during the last quarter. Finally, Van ECK Associates Corp raised its position in shares of Jazz Pharmaceuticals by 11.4% during the 3rd quarter. Van ECK Associates Corp now owns 60,211 shares of the specialty pharmaceutical company’s stock valued at $6,691,000 after acquiring an additional 6,157 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,110 shares of company stock valued at $720,160. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on JAZZ. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. TD Cowen dropped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Piper Sandler lowered their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Three investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $175.00.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $121.65 on Friday. The firm has a market capitalization of $7.35 billion, a PE ratio of 17.13, a P/E/G ratio of 1.07 and a beta of 0.57. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a 50-day moving average price of $112.22 and a 200 day moving average price of $110.35. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.